Editor’s Voice: November – marketing excellence and diabetes
pharmaphorum’s Hannah Blake provides an overview of the content published during the month of November on the topics of marketing excellence and metabolic diseases / diabetes. She also shares what’s coming up as we near the end of 2013…
It’s here – the countdown to Christmas and the New Year has begun. Just where has this year gone?
We’ve had some great pieces been published in our various focus months over the last 10 months, and November was no different, featuring a high level of expert thought leadership in the areas of marketing excellence and metabolic diseases / diabetes.
Here are my content highlights from our two themes:-
• Starting off our marketing excellence month, Sunil Ramkali discussed how to deliver an effective global strategic brand plan.
• Ash Rishi, from COUCH., wrote a four-piece series, questioning whether pharma marketers were accomplishing their goals, how social media fits in with pharma marketing, whether marketers are put off by heavy regulations and why you should understand different behaviours in order to achieve successful marketing excellence.
• Can healthcare serve to jumpstart stagnant economies? Bill Trombetta, from St. Joseph’s University in the United States, discussed this in his article.
“We’ve had some great pieces been published in our various focus months over the last 10 months, and November was no different…”
• Cutting Edge Information’s Elio Evangelista shares his tips on how companies can fully (and successfully) embrace the patient focus when it comes to pharma marketing.
• While Extrovertic’s Dorothy Wetzel outlined three major marketplace changes and detailed ways to thrive during healthcare reform in her article.
• Plus, Alexandra Fulford shared her thoughts on what every pharma marketer should do and not do when it comes to social media.
• For our metabolic diseases focus, Kerri Sparling, blogger and type 1 diabetes patient, highlighted the benefits of online patient communities for the wellbeing of patients.
• And, in her article, Mavis Dixon from Ayogo shared ten top tips for motivating diabetes patients to stick to fitness regimes in order to boost their health.
But make sure you don’t miss out on these great content pieces either:-
• Velocity Pharmaceuticals’ CEO David Collier explored the challenges in pharma partnerships and questioned why it is so hard for big pharma companies to invest in smaller startup biotechnology companies.
• Daniel Ghinn spoke with the man behind Pfizer Sweden’s environmental and responsibility blog, Bengt Mattson, about the value of personality in pharma social media.
“We’ve also been busy updating our media section…”
• Serkan Erkovan shared his thoughts on digital within pharma in our latest ‘digital health perspective‘ interview with pharmaphorum’s Rebecca Aris.
• UBC’s Jennifer Allen and Charlie Bell discussed the ever-changing role of nurses within the healthcare industry, looking at how nurses today are not only limited to helping patients within hospitals, but provide medical education and adherence services via the phone as well.
• And finally, Adelphi explored how appropriate publication of valuable and robust market research insights can provide a golden opportunity to create more compelling education for healthcare professionals, and ultimately improve patient care.
We’ve also been busy updating our media section with a brand new and exclusive white paper from Doctors.net.uk. Titled “Doctor networks: The rules of engagement for pharma” this white paper, in association with pharmaphorum, addresses:
• Where doctors like to engage with pharma
• What sort of information and content doctors are seeking online
• How to make content easy to consume for doctors
• Why it is important to encourage online discussion between doctors
You can download the white paper for free here: https://pharmaphorum.com/white-papers/the-rules-of-engagement-for-pharma
Coming up on pharmaphorum
Next month, we’ll be publishing content around the theme of sales effectiveness. From how to implement customer-centric sales strategies to overcome physician access challenges, to whether now is the time to recruit more women into sales, to how sales efficacy is becoming an integral part of business life, make sure you keep your eyes peeled for some excellent content.
Plus, this week we’ll be hosting our first webinar!
“Is there common ground for engagement between doctors and pharma?” will take place at 1pm GMT / 2pm CET on Tuesday 5th December.
“Plus, this week we’ll be hosting our first webinar!”
Hosted by pharmaphorum’s CEO Paul Tunnah, a panel of experts – the CEO of Doctors.net.uk, a GP partner, Consultant Physician, and Bristol-Myers Squibb’s Director eBusiness Europe – will discuss:
• What information doctors want from pharma online
• How online engagement differs from real world interaction
• The best routes to engage with doctors online
To register for this webinar please visit: https://www.brighttalk.com/webcast/9977/91329
One last thing…
And finally, I’d like to take a moment to say that I will be leaving pharmaphorum at the end of this week to pastures new. I’ve enjoyed my time here working with Paul and the team and wish them, and pharmaphorum, all the best for the future.
May we continue to see great content for many years to come!
About the author:
Hannah joined pharmaphorum in early 2012, after graduating with a degree in Magazine Journalism & Feature Writing in 2011, and leads our news coverage, in addition to liaising with new and existing feature authors. With over three years’ experience working within the journalism industry alongside university, Hannah has written for a number of different print and online publications, within the women’s lifestyle, travel and celebrity sectors. Now focussed on the pharma sector with her role at pharmaphorum, Hannah is embracing the challenges of working within a fast growing media organisation in this rapidly changing industry sector.
Please direct any content queries to our Managing Editor, Rebecca Aris, at Rebecca@pharmaphorum.com.
Is there common ground for engagement between doctors and pharma?